MedTrace Logo

Toripalimab, Induction Chemotherapy, Radiation Therapy With Omega-3 for Locally Advanced Nasopharyngeal Carcinoma

NCT07136519 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2025-08-22

No results posted yet for this study

Summary

The aim of this study is to evaluate the efficacy, adverse reactions, nutritional status analysis, and quality of life analysis of Toripalimab Plus Induction Chemotherapy Followed by Radiation Therapy Combined with Omega-3 in the treatment of locally advanced nasopharyngeal carcinoma.

Conditions

  • Nasopharyngeal Carcinoma (NPC)

Interventions

DRUG

Toripalimab

240mg Q3W

DIETARY_SUPPLEMENT

Omega-3

During radiotherapy, take 6 capsules once a day

RADIATION

radiotherapy

radiotherapy

DRUG

Paclitaxel (albumin bound)

260mg/m2 d1,Q3W

DRUG

Cisplatin

80mg/m2 d2, Q3W

Sponsors & Collaborators

  • Affiliated Hospital of Guangdong Medical University

    lead OTHER

Principal Investigators

  • Haiqing Luo, doctor · Guangdong Medical University Affiliated Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-08-22
Primary Completion
2029-12-31
Completion
2029-12-31

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07136519 on ClinicalTrials.gov